Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making

BACKGROUND: It is widely acknowledged that there is value in examining cancers for genomic aberrations via next-generation sequencing (NGS). How commercially available NGS platforms compare with each other, and the clinical utility of the reported actionable results, are not well known. During the c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Onco Targets Ther
Main Authors: Weiss, Glen J, Hoff, Brandi R, Whitehead, Robert P, Sangal, Ashish, Gingrich, Susan A, Penny, Robert J, Mallery, David W, Morris, Scott M, Thompson, Eric J, Loesch, David M, Khemka, Vivek
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2015
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4423502/
https://ncbi.nlm.nih.gov/pubmed/25960669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S81995
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados